Dyne Therapeutics Inc (DYN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dyne Therapeutics Inc (DYN) has a cash flow conversion efficiency ratio of -0.115x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-111.83 Million) by net assets ($972.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dyne Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Dyne Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Dyne Therapeutics Inc for a breakdown of total debt and financial obligations.
Dyne Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dyne Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sanxiang Advanced Materials
SHG:603663
|
0.046x |
|
American Eagle Outfitters Inc
NYSE:AEO
|
0.032x |
|
Q2 Holdings
NYSE:QTWO
|
0.096x |
|
HC Semitek Corp
SHE:300323
|
-0.048x |
|
Koza Altin Isletmeleri AS
IS:KOZAL
|
0.128x |
|
Liechtensteinische Landesbank AG
SW:LLBN
|
-0.279x |
|
CECEP Solar Energy Co Ltd
SHE:000591
|
0.112x |
|
Fortuna Silver Mines Inc
TO:FVI
|
0.066x |
Annual Cash Flow Conversion Efficiency for Dyne Therapeutics Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Dyne Therapeutics Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Dyne Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $972.13 Million | $-403.21 Million | -0.415x | +10.65% |
| 2024-12-31 | $629.84 Million | $-292.37 Million | -0.464x | +77.48% |
| 2023-12-31 | $91.29 Million | $-188.16 Million | -2.061x | -238.53% |
| 2022-12-31 | $252.36 Million | $-153.65 Million | -0.609x | -87.49% |
| 2021-12-31 | $368.20 Million | $-119.56 Million | -0.325x | -139.05% |
| 2020-12-31 | $342.37 Million | $-46.51 Million | -0.136x | +83.89% |
| 2019-12-31 | $14.04 Million | $-11.83 Million | -0.843x | -198.79% |
| 2018-12-31 | $-4.88 Million | $-4.16 Million | 0.853x | +177.34% |
| 2017-12-31 | $1.90 Billion | $585.00 Million | 0.308x | -7.04% |
| 2016-12-31 | $2.04 Billion | $676.00 Million | 0.331x | +928.71% |
| 2015-12-31 | $2.92 Billion | $94.00 Million | 0.032x | +256.91% |
| 2014-12-31 | $3.02 Billion | $-62.00 Million | -0.021x | -125.90% |
| 2013-12-31 | $2.21 Billion | $175.00 Million | 0.079x | +550.46% |
| 2012-12-31 | $2.50 Billion | $-44.00 Million | -0.018x | +2.26% |
| 2011-12-31 | $1.11 Billion | $-20.00 Million | -0.018x | -111.68% |
| 2010-12-31 | $2.75 Billion | $423.00 Million | 0.154x | +239.92% |
| 2009-12-31 | $2.98 Billion | $135.00 Million | 0.045x | -36.29% |
| 2008-12-31 | $4.49 Billion | $319.00 Million | 0.071x | -5.53% |
| 2007-12-31 | $4.53 Billion | $341.00 Million | 0.075x | -- |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more